Completed
Open-Label Phase 1/2 Study of VELCADE for Injection in Patients With Light-chain (AL)-Amyloidosis
NCT00298766
- Conditions
- Amyloidosis, Metabolic Diseases, Nutritional and Metabolic Diseases, +1 more
- Locations
-
- Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute Los Angeles, California, United States
- Winship Cancer Center - Emory Clinic School of Medicine Atlanta, Georgia, United States
- Boston Medical Center Boston, Massachusetts, United States
- MSKCC New York, United States